Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2022).
Revenue
€ 5.4 million
Profit
Healthy€ 1.3 million
▼ 23% vs 2024
Debts
Low€ 978,856
▼ 5% vs 2024
BETAPLUS PHARMA from Sint-Lambrechts-Woluwe, company number BE0479037369, closed financial year 2025 with a result of € 1.3 million after tax. For that financial year BETAPLUS PHARMA recorded revenue of € 5.4 million and equity of € 22.3 million. Compared with financial year 2024, the result moved from € 1.6 million to € 1.3 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 3, 2026.
What happened at BETAPLUS PHARMA?
What happened at BETAPLUS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Beryle ZANY stepped down as director. NBB
- Philippe DEHASPE stepped down as director. NBB
- Stephan MAIRLOT stepped down as director. NBB
- François JAMAR stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.3 million (▼ 23% vs 2024). filed late Source: NBB ↗
- Benoit WOESSMER stepped down as director. NBB
- Xavier DEFOURT stepped down as director. NBB
- Beryle ZANY became a director. NBB
In short
From € 1.6 million profit in 2021 to € 1.3 million profit in 2025.
Paid € 2.5 million in corporate taxes since 2021.
Best year ever: 2024, with € 1.6 million profit.
On average € 239,900 of value added per employee in 2025.
A new publication or filing at BETAPLUS PHARMA? We notify you, reason included.
Follow BETAPLUS PHARMANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
François JAMAR
Director
since 2021 · until 2028
Benoit WOESSMER
Director
since 2021 · until 2025
since 2020 · until 2025
Beryle ZANY
Director
since 2025 · until 2031
Stephan MAIRLOT
Managing director
since 2023 · until 2029
Philippe DEHASPE
Director
Also active at: Cliniques universitaires Saint-Luc, Le Roseau, LE BOSQUET +4 more
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Hippokrateslaan 10 box 1527
1200 Sint-Lambrechts-Woluwe
Hippokrateslaan 10
1200 Sint-Lambrechts-Woluwe
Active since 3 February 2003
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 33 companies are registered at this address.
Societe Belge d'Urologie
€ 13,934 gross margin · 2023
Cliniques universitaires Saint-Luc same network
€ 857.9 million revenue · 2025
Coeur, Sport et Santé
Association belge de Médecine nucléaire - belgische Vereniging voor Nucleaire Geneeskunde
Enfance et Cerveau - Het Kind en het Zenuwstelsel
+28 more
Details
- Company number
- 0479.037.369
- VAT number
- BE 0479.037.369
- Registered office
- Hippokrateslaan 10 bus 1527, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- BETAPLUS PHARMA · betaplus
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 December 2002
- Peppol
- Active · Active since 31 Mar 2026
- Activities · NACE
Vervaardiging van geneesmiddelen
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten